These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 8935810)

  • 1. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.
    Pilowsky LS; Busatto GF; Taylor M; Costa DC; Sharma T; Sigmundsson T; Ell PJ; Nohria V; Kerwin RW
    Psychopharmacology (Berl); 1996 Mar; 124(1-2):148-53. PubMed ID: 8935810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.
    Tauscher J; Küfferle B; Asenbaum S; Fischer P; Pezawas L; Barnas C; Tauscher-Wisniewski S; Brücke T; Kasper S
    Psychopharmacology (Berl); 1999 Jan; 141(2):175-81. PubMed ID: 9952042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
    Bigliani V; Mulligan RS; Acton PD; Ohlsen RI; Pike VW; Ell PJ; Gacinovic S; Kerwin RW; Pilowsky LS
    Psychopharmacology (Berl); 2000 Jun; 150(2):132-40. PubMed ID: 10907666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
    Bernardo M; Parellada E; Lomeña F; Catafau AM; Font M; Gómez JC; López-Carrero C; Gutiérrez F; Pavía J; Salamero M
    Psychiatry Res; 2001 Aug; 107(2):87-97. PubMed ID: 11530275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.
    Dresel S; Mager T; Rossmüller B; Meisenzahl E; Hahn K; Möller HJ; Tatsch K
    Eur J Nucl Med; 1999 Aug; 26(8):862-8. PubMed ID: 10436199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications.
    Frankle WG; Gil R; Hackett E; Mawlawi O; Zea-Ponce Y; Zhu Z; Kochan LD; Cangiano C; Slifstein M; Gorman JM; Laruelle M; Abi-Dargham A
    Psychopharmacology (Berl); 2004 Oct; 175(4):473-80. PubMed ID: 15083259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine.
    Schmitt GJ; Meisenzahl EM; Dresel S; Tatsch K; Rossmüller B; Frodl T; Preuss UW; Hahn K; Möller HJ
    J Psychopharmacol; 2002 Sep; 16(3):200-6. PubMed ID: 12236625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine.
    Raedler TJ; Knable MB; Lafargue T; Urbina RA; Egan MF; Pickar D; Weinberger DR
    Psychiatry Res; 1999 Apr; 90(2):81-90. PubMed ID: 10482380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia.
    Lavalaye J; Linszen DH; Booij J; Reneman L; Gersons BP; van Royen EA
    Psychiatry Res; 1999 Nov; 92(1):33-44. PubMed ID: 10688158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole--a 123I IBZM single photon emission tomography (SPET) study.
    Pilowsky LS; O'Connell P; Davies N; Busatto GF; Costa DC; Murray RM; Ell PJ; Kerwin RW
    Psychopharmacology (Berl); 1997 Mar; 130(2):152-8. PubMed ID: 9106913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between olanzapine and haloperidol on procedural learning and the relationship with striatal D2 receptor occupancy in schizophrenia.
    Paquet F; Soucy JP; Stip E; Lévesque M; Elie A; Bédard MA
    J Neuropsychiatry Clin Neurosci; 2004; 16(1):47-56. PubMed ID: 14990759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.
    Klemm E; Grünwald F; Kasper S; Menzel C; Broich K; Danos P; Reichmann K; Krappel C; Rieker O; Briele B; Hotze AL; Möller HJ; Biersack HJ
    Am J Psychiatry; 1996 Feb; 153(2):183-90. PubMed ID: 8561197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study.
    Pilowsky LS; Costa DC; Ell PJ; Murray RM; Verhoeff NP; Kerwin RW
    Psychol Med; 1993 Aug; 23(3):791-7. PubMed ID: 7901865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
    Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
    J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123I-IBZM SPECT study.
    Kasper S; Tauscher J; Küfferle B; Barnas C; Hesselmann B; Asenbaum S; Podreka I; Brücke T
    Psychopharmacology (Berl); 1998 Apr; 136(4):367-73. PubMed ID: 9600582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
    de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
    Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study.
    Meisenzahl EM; Dresel S; Frodl T; Schmitt GJ; Preuss UW; Rossmüller B; Tatsch K; Mager T; Hahn K; Möller HJ
    J Psychopharmacol; 2000; 14(4):364-70. PubMed ID: 11198054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol.
    Tauscher J; Küfferle B; Asenbaum S; Tauscher-Wisniewski S; Kasper S
    Psychopharmacology (Berl); 2002 Jun; 162(1):42-9. PubMed ID: 12107616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study.
    Busatto GF; Pilowsky LS; Costa DC; Ell PJ; Verhoeff NP; Kerwin RW
    Psychopharmacology (Berl); 1995 Jan; 117(1):55-61. PubMed ID: 7536945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
    Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
    Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.